Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acetohexamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gliclazide SCHEMBL16387 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3TSHRTDP1 | |
| Gliclazide SCHEMBL291434 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3TSHRTDP1 | |
| Gliclazide SCHEMBL1537023 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3TSHRTDP1 | |
| Gliclazide SCHEMBL13723694 | 0.85 | ALDH1A1 (0.67) | ALDH1A1LMNAAKR1C3TSHRTHRB | |
| Gliclazide SCHEMBL239075 | 0.84 | ALDH1A1 (0.97) | ALDH1A1LMNAAKR1C3TSHRTDP1 | |
| Acetohexamide SCHEMBL37620 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNATSHRTHRBBLM | |
| Acetohexamide SCHEMBL15669221 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNATSHRTHRBBLM | |
| Gliclazide SCHEMBL6344915 | 0.82 | ALDH1A1 (0.88) | ALDH1A1LMNAAKR1C3TSHRADORA3 | |
| Heptolamide SCHEMBL1814750 | 0.82 | ADORA3 (1.00) | ALDH1A1LMNAAKR1C3TSHRTHRB | |
| Glycyclamide SCHEMBL49386 | 0.82 | ADORA3 (1.00) | ALDH1A1LMNAAKR1C3TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558220-B1 | ORAL COMPOSITIONS FOR TREATMENT OF DIABETES | WOCKHARDT LTD (IN) | 2010-02-10 | — | — | EP | claimed |
| US-8551524-B2 | Anti-diabetic combinations | IYCUS, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120041069-A1 | SGLT2 INHIBITOR DOSAGE FORMS | NECTID INC. | 2012-02-16 | — | — | US | disclosed |
| WO-2010045656-A2 | NOVEL SGLT2 INHIBITOR DOSAGE FORMS | NECTID, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100074950-A1 | ANTI-DIABETIC COMBINATIONS | NECTID INC. | 2010-03-25 | — | — | US | disclosed |
| EP-1558220-B1 | ORAL COMPOSITIONS FOR TREATMENT OF DIABETES | WOCKHARDT LTD (IN) | 2010-02-10 | — | — | EP | disclosed |
| EP-2139464-A1 | ANTI-DIABETIC COMBINATIONS COMPRISING A SLOW RELEASE BIGUANIDE COMPOSITION AND AN IMMEDIATE RELEASE DIPEPTIDYL PEPTIDASE IV INHIBITOR COMPOSITION | Nectid, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008113000-A1 | ANTI-DIABETIC COMBINATIONS COMPRISING A SLOW RELEASE BIGUANIDE COMPOSITION AND AN IMMEDIATE RELEASE DIPEPTIDYL PEPTIDASE IV INHIBITOR COMPOSITION | NECTID, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080064701-A1 | Anti-diabetic combinations | NECTID, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070172525-A1 | Anti-diabetic combinations | NECTID, INC. | 2007-07-26 | — | — | US | disclosed |
| WO-2005009412-A1 | ORAL COMPOSITIONS FOR TREATMENT OF DISEASES | WOCKHARDT LIMITED (IN) | 2005-02-03 | — | — | WO | disclosed |
| US-20040147564-A1 | Combinations of glimepiride and the thiazolidinedione for treatment of diabetes | WOCKHARDT LIMITED (IN) | 2004-07-29 | — | — | US | disclosed |
| EP-1107763-B1 | CONTROLLED RELEASE TABLET COMPRISING A HYPOGLYCEMIC DRUG AND AN ANTIHYPERGLYCEMIC DRUG | ANDRX PHARMACEUTICALS INC (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030224046-A1 | Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent | WOCKHARDT LIMITED (IN) | 2003-12-04 | — | — | US | disclosed |
| US-20030219482-A1 | Multiparticulate compositions for once-a-day administration | WOCKHARDT LIMITED (IN) | 2003-11-27 | — | — | US | disclosed |
| US-20030187074-A1 | Oral compositions for treatment of diabetes | WOCKHARDT LIMITED (IN) | 2003-10-02 | — | — | US | disclosed |
| US-6284275-B1 | Controlled release tablet having a unitary core | ANDRX PHARMACEUTICALS, INC. | 2001-09-04 | — | — | US | disclosed |
| EP-1107763-A1 | CONTROLLED RELEASE TABLET COMPRISING A HYPOGLYCEMIC DRUG AND AN ANTIHYPERGLYCEMIC DRUG | ANDRX PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6099862-A | CORE, SEAL COATINGS, SEMIPERMEABLE MEMBRANE, PASSAGEWAY | ANDRX CORPORATION (US) | 2000-08-08 | — | — | US | disclosed |
| WO-2000012097-A1 | CONTROLLED RELEASE TABLET COMPRISING A HYPOGLYCEMIC DRUG AND AN ANTIHYPERGLYCEMIC DRUG | ANDRX PHARMACEUTICALS, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041069-A1 | SGLT2 INHIBITOR DOSAGE FORMS | SLC5A2, SLC5A1, SLC2A4 | ALDH1A1 2220/4885LMNA 3577/4885AKR1C3 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.